UFP Technologies, Inc., a leading designer and manufacturer of interior protective packaging solutions, recently announced the company’s third quarter earnings, ended September 30, 2009, with net income of $2.1 million or $0.34 per diluted share. Sales for the third quarter totaled $27.6 million, slightly higher than 2008 third quarter sales of $27.5 million.

For the nine-month period ended September 30, 2009, UFP Technologies reported net income of $3.0 million or $0.49 per diluted common share outstanding, compared to $4.0 million or $0.63 per diluted common share outstanding for the corresponding nine months in 2008. Sales over the same time period totaled $70.2 million, compared to $84.0 million for the same nine-month period in 2008. Due to bargain purchase gains from acquisitions during the year, earnings per share for the nine-month period ended September 30, 2009 was $0.13.

R. Jeffrey Bailly, UFP Technologies’ chairman, chief executive officer and president, stated, “I am

...

Sony Corp. (NYSE ADR: SNE) is facing the first consecutive annual loss of its 63-year history.

The Tokyo-based company lost $1.1 billion (98.9 billion yen) last year, and it expects to lose another $1.4 billion (120 billion yen) in its fiscal year ending March 31.  That would be Sony’s first back-to-back annual loss since the company went public in 1958.

And despite renewed optimism within its ranks, Sony still faces a plethora of challenges, including a questionable direction, cost-conscious consumers and a strengthening yen.

The onetime bellwether of the electronics industry has seen its market share crumble in almost every category: Nintendo Co. Ltd.’s (OTC ADR: NTDOY) Wii game console has supplanted Sony’s PlayStation brand, Sony has given up its lead in portable media players to Apple Inc.’s (Nasdaq: AAPL) iPod, and Samsung Electronics Co. Ltd. is now the world’s largest seller of televisions.

Hoping to turn the

...

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), today told the investment community of partial success in the recently completed Phase 3 trial in Thailand of a candidate HIV/AIDS vaccine. According to the press release, this completed study represents the first HIV/AIDS vaccine trial to show prevention of infection.

Robert McNally, Ph.D., Chief Executive Officer and President stated, “The results are highly encouraging for the clinical studies of our HIV/AIDS vaccine and we congratulate the Thai ministry of Public Health for successful conduct of a groundbreaking trial that included 16,000 volunteers and was supported by multiple agencies including the U.S. Army and the U.S. National Institutes of Health (NIH).”

“The partial success of this trial is very important to the GeoVax vaccine, because the vaccine tested in Thailand, like the GeoVax vaccine, was designed to elicit both T cells and antibody,” commented Dr. Harriet

...

Syntel, Inc. (SYNT) continues its streak of earnings surprises as estimates and share price spikes.

Company Description

Syntel provides tech services to companies and public entities. Services are divided into the e-Business, Application Outsourcing, and Teamsourcing.

Tops Forecasts

On Jul 29 Syntel reported second-quarter results that included earnings per share of 61 cents, topping the Zacks Consensus Estimate by a dime. Total revenue dipped to $100 million from $103 million, but the margins improved significantly to 48.2%.

CEO Speaks

"Syntel was encouraged by improved stabilization in the marketplace and the increasingly positive discussions initiated with our clients during the quarter," said Chief Executive Officer and President Keshav Murugesh.

Estimates Spike

Following the release, the full-year estimates for this year and next have spiked. The Zacks Consensus Estimate for 2009 is now $2.43, up from $2.20. Estimates for next year are averaging $2.40, a slight dip year-over-year, but up from $2.11.

This

...

Are techs back and ready for another run-up? No one really knows. If technology plays are poised for a resurgence, the catalysts of today are much different than those of the past. However, the support level that the tech-laden Nasdaq recently touched was not too far off from the bottom it hit in late 2002.

After seeing the 2002 bottom, the Nasdaq gained approximately 160% during the 5 years that followed before tumbling again. Will the Nasdaq, coming off a recent bottom, bring similar or bigger profits? We'll have to wait and see. But why watch from the sidelines? Why not pick a few solid tech plays and ride the wave higher should there be another 5-year surge.

Using the Research Wizard, I found Zacks #1 Rank (Strong Buy) plays that are poised to deliver strong results over the long-term.

3 Tech Plays

Western Digital Corp. (WDC)

...